Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + bevacizumab with or without upfront paclitaxel for first-line HER2-positive metastatic breast cancer
NL-OMON25011Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab, bevacizumab and paclitaxel in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free survival rate at 1 year. Started Apr 2009; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON25011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25011.